钠-葡萄糖协同转运蛋白2抑制剂使用与2型糖尿病患者肝脏相关事件风险:观察性队列研究的Meta分析
该Meta分析纳入8项观察性队列研究、共626,104例2型糖尿病患者,比较钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂与其他降糖药对新发主要不良肝脏相关结局(MALOs)的影响。中位随访2.7年,SGLT2抑制剂使用与MALOs风险显著降低相关(随机效应HR 0.83,95%CI 0.72-0.95;I²=83.1%),与肝脏相关死亡风险显著降低相关(HR 0.64,95%CI 0.50-0.82;I²=0%)。
要点
- SGLT2抑制剂使用与2型糖尿病患者MALOs风险显著降低相关(HR 0.83,95%CI 0.72-0.95)。
- SGLT2抑制剂使用与肝脏相关死亡风险显著降低相关(HR 0.64,95%CI 0.50-0.82)。
- 与二肽基肽酶4抑制剂、二甲双胍或吡格列酮比较时MALOs风险显著降低,与胰高血糖素样肽1受体激动剂比较则未观察到显著降低。
核心结论
- SGLT2抑制剂使用与2型糖尿病患者主要不良肝脏相关结局(MALOs)风险降低相关。
研究设计与样本
- 研究系统检索三个大型电子数据库自建库至2025年1月,纳入比较SGLT2抑制剂与其他降糖药的活性对照、新使用者队列研究。
- 共纳入8项队列研究,汇总数据包括626,104例2型糖尿病患者,其中SGLT2抑制剂新使用者397,806例,其他降糖药新使用者228,298例。
- 主要结局为MALOs发生率,定义为肝脏失代偿事件、肝细胞癌、肝移植或肝脏相关死亡的复合终点;次要结局为上述各事件单独发生。
- 采用随机效应模型进行Meta分析。
主要发现
- 中位随访2.7年期间,SGLT2抑制剂使用与MALOs风险显著降低相关(随机效应HR 0.83,95%CI 0.72-0.95;I²=83.1%)。
- SGLT2抑制剂使用与肝脏相关死亡风险显著降低相关(HR 0.64,95%CI 0.50-0.82;I²=0%)。
- 与二肽基肽酶4抑制剂、二甲双胍或吡格列酮比较时,MALOs风险显著降低;与胰高血糖素样肽1受体激动剂比较时未观察到显著降低。
- 敏感性分析未改变上述结果;漏斗图未显示显著发表偏倚。
局限性
- 纳入队列研究的观察性设计是主要局限性之一。
- 异质性水平高(MALOs分析I²=83.1%)是主要局限性之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is uncertainty regarding effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the risk of major adverse liver-related outcomes (MALOs). PURPOSE: We performed a meta-analysis of observational cohort studies to quantify the magnitude of the association between SGLT2 inhibitor use and risk of developing MALOs for people with type 2 diabetes mellitus (T2DM). DATA SOURCES: We systematically reviewed three large electronic databases from inception to January 2025. STUDY SELECTION: We included active-comparator, new-user cohort studies with comparison of SGLT2 inhibitors versus other glucose-lowering medications in patients with T2DM. DATA EXTRACTION: The primary outcome was incidence rate of MALOs defined as a composite of hepatic decompensation events, hepatocellular carcinoma, liver transplantation, or liver-related deaths. Secondary outcomes included each of the above as individual events. Meta-analysis was performed with random-effects models. DATA SYNTHESIS: We identified eight cohort studies with aggregate data on 626,104 patients with T2DM (397,806 SGLT2 inhibitor new users and 228,298 new users of other glucose-lowering agents). During a median of 2.7 years, SGLT2 inhibitor use was associated with significantly lower risk of MALOs (random-effects hazard ratio 0.83, 95% CI 0.72-0.95; I2 = 83.1%) and liver-related deaths (0.64, 0.50-0.82; I2 = 0%). The significant risk reduction in MALOs was observed in comparisons of SGLT2 inhibitors with dipeptidyl peptidase 4 inhibitors, metformin, or pioglitazone but not glucagon-like peptide 1 receptor agonists. Sensitivity analyses did not modify these results. A funnel plot did not show significant publication bias. LIMITATIONS: Observational design of the cohort studies and high level of heterogeneity are the main limitations. CONCLUSIONS: SGLT2 inhibitor use was associated with lower risk of MALOs for patients with T2DM.
引用
- Mantovani A, Morandin R, Lando MG, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies. Diabetes Care. 2025. PMID: 40392994. doi:10.2337/dc25-0282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。